- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05542121
Rehab CARES In USA: Clinical Trial
Rehabilitation Using Community-Based Affordable Robotic Exercise Systems (Rehab CARES)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19146
- Penn Medicine Rittenhouse
-
Philadelphia, Pennsylvania, United States, 19145
- Mercy Living Independently for Elders (L.I.F.E) - West Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 55 and older (based on who is admitted to the CBR site)
- >3 months post-stroke
- Stroke diagnosis
- Diagnosis of hemiparesis as a result of stroke (verified by radiology data)
- Motor control score on Upper Extremity Fugl-Meyer scale > 15 and < 60;
- Able to understand and speak
- Upper arm manual muscle strength scores >1
- Pain Scores < 8 based on NIH Pain Intensity Scale
Exclusion Criteria:
- no cerebellum lesions due to stroke
- severe cognitive function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Standard of Care
60 min OT sessions; 3 sessions per week; for 4 weeks;-- augmented Standard therapy - consisting of PT, OT and SLP.
Clinical Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2).
|
60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP
|
|
Experimental: Robot-Assisted Therapy with Rehab CARES system
60 min sessions; 3 sessions per week; for 4 weeks;----of Upper Limb therapy using 1 or more affordable robots. Robot sessions can be group play and/or single play. Robot Assessment (B1-pre, B2-post, B3-follow-up#1, B4-follow-up#2) |
60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes.
The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced.
The 60 minutes will be broken up into 15-minute training intervals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Motivation
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Measured by the Self-Assessment Manikin (SAM) scale which consist of 3 subscales: enjoyment, engagement, and control.
Each subscale is from 0 to 9. For enjoyment and engagement the higher score is the better and for control the lower score is better.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Motor Control
Time Frame: After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)
|
Measured by Upper Extremity Fugl-Meyer Assessment (UE-FM); scale is out of 66.
A lower score means more impaired.
|
After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)
|
|
Gross Hand Function
Time Frame: After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)
|
Measured by Box and Block (BnB) Test; metric # of blocks transferred.
A higher score means less impaired.
|
After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)
|
|
Hand Dexterity
Time Frame: After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)
|
Measured by NIH Toolbox 9-Hole Pegboard Dexterity Test; metric time and # of peg transferred over time.
A higher number of pegs means less impaired.
|
After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)
|
|
Upper Extremity Function
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Measured by Neuro-QoL: Upper Extremity Function - Fine Motor, ADL Short Form.
Short form is a self-report on 8 items to assesses fine motor function and activity of daily living in upper arm.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Quality of life (Participation)
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Measured by Neuro-QoL: Ability to Participate in Social Role and Activities Short Form.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Quality of life (Satisfaction)
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Measured by Neuro-QoL Satisfaction with Social Roles and Activities Short Form.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Spatial Attention
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Measured by changes in Color Trails 1.A timed trail making assessment.
A faster time result is better.
Timed results are normalized by age and education and reported as a normalized z-score.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Executive Function
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Measured by performance on Color Trails 2. A timed trail making assessment.
A lower time is better.
Timed results are normalized by age and education and reported as a normalized z-score.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Active Joint Range of Motion (ROM)
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Range of Motion joint testing of the upper limb.
Subjects shoulder, elbow, and wrist joint active joint movements are evaluated in the impaired arm.
Reported in degrees.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Passive Joint Range of Motion (ROM)
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Range of Motion joint testing of the upper limb.
Subjects shoulder, elbow, and wrist joint passive joint movements are evaluated in the impaired arm.
Reported in degrees.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Grip Strength
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Measured by NIH toolbox Grip Strength Test.
The amount of pound-force is measured.
The higher pound-force is better.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Exertion Level
Time Frame: at each of 12 therapy sessions
|
Measured by score on Borg Exertion Scale.
Score is from 0 to 10. 0 is low and 10 is max.
Subjects are asked to report pain experienced during a 60 minute session.
Exertion between 0 and 6 is expected.
|
at each of 12 therapy sessions
|
|
Pain Level
Time Frame: at each of 12 therapy sessions
|
Measured by score on Visual Analog Pain Scale.
Patients indicate a pain score is from 0 to 10. 0 is low and 10 is max.
Subjects are asked to report pain experienced during a 60 minute session.
Pain < 4 is expected.
|
at each of 12 therapy sessions
|
|
Usability
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Measured by score on System Usability Scale.
Score is from 0 to 100.
0 is low and 100 is max.
A score greater than or equal to 68 is ideal.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Work Load
Time Frame: at pre, at post-intervention (after 12 sessions), at follow-up
|
Measured by NASA TLX Task Demand Scale.
The scale consist of 6 questions scored on a likert scale of 0 to 21.
The responses are processed to define a workload score.
A workload score at or above 37 which is MOD-HIGH is expected.
|
at pre, at post-intervention (after 12 sessions), at follow-up
|
|
Cognition
Time Frame: After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)
|
Measured by Montreal Cognitive Assessment (MocA)
|
After 12 sessions (post-pre), after follow-up at 4 weeks (post-follow-up)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michelle J Johnson, PhD, University of Pennsylvania
- Principal Investigator: Alwyn Johnson, MS, Recupero Robotics LLC
Publications and helpful links
General Publications
- Azar RM, Sobotka NS, Cacchione P, Mendonca RJ, Johnson MJ. Evaluating the Relationship Between Motor and Cognitive Impairment and Lesion Size and Location Post-Stroke Using CT Scans. IEEE Int Conf Rehabil Robot. 2025 May;2025:1467-1472. doi: 10.1109/ICORR66766.2025.11063052.
- Shang Y, Bahrami S, Gaardsmoe S, Johnson A, Johnson MJ, Diefenbach P. General Purpose Haptic/Biometric-Based Dynamic Difficulty Adjustment for Post-Stroke Upper-Limb Rehabilitation Games. IEEE Int Conf Rehabil Robot. 2025 May;2025:248-253. doi: 10.1109/ICORR66766.2025.11062998.
- Waters EL, Johnson MJ. Motor Learning in Robot-Based Haptic Dyads: A Review. IEEE Trans Haptics. 2024 Oct-Dec;17(4):510-527. doi: 10.1109/TOH.2024.3379035. Epub 2024 Dec 19.
- Waters EL, Mendonca RJ, Cacchione PZ, Johnson MJ. TheraDyad: Feasibility of an Affordable Robot for Multi-User Stroke Rehabilitation. Proc IEEE RAS EMBS Int Conf Biomed Robot Biomechatron. 2024 Sep;2024:1498-1503. doi: 10.1109/biorob60516.2024.10719912. Epub 2024 Oct 23.
- Waters EL, Azar R, Opong-Duah J, Gaardsmoe S, Johnson A, Mendonca RJ, Cacchione PZ, Johnson MJ. Towards an Optimal Model of Post-Stroke Sensorimotor Control. IEEE Int Conf Rehabil Robot. 2025 May;2025:1313-1319. doi: 10.1109/ICORR66766.2025.11063066.
- Meng NY, Waters EL, Lin G, Gaardsmoe S, Johnson A, Hallock LA, Mendonca RJ, Cacchione PZ, Johnson MJ. Analysis of Induced Muscle Activations by an Affordable, Reconfigurable Robot for Comprehensive Post-Stroke Rehabilitation. IEEE Int Conf Rehabil Robot. 2025 May;2025:1361-1367. doi: 10.1109/ICORR66766.2025.11063060.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Paralysis
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Stroke
- Hemiplegia
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Standard of Care
Other Study ID Numbers
- 853607
- R42HD104325 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
It is a priority of the research team to share primary data collected as a result of this project with other researchers and the National Institute of Health and associated funding agents. Findings will be disseminated within a reasonable time via newsletters sponsored by the institutions involved, peer-reviewed conference papers and journals. All journal papers will be placed on PubMed and made publically accessible. All acknowledgements will clearly define the funding agency and follow guidelines stipulated by the NIH. Copies of all publications will provided promptly. All copyright procedures will comply with the standard of NIH copyright clause.
After study completion, de-identified data sets will be available to NIH and to other investigators contingent on the execution of relevant institutional data use agreements.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.